|Bid||0.00 x 800|
|Ask||0.00 x 1300|
|Day's Range||18.52 - 19.29|
|52 Week Range||9.85 - 25.02|
|Beta (5Y Monthly)||0.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.50|
The temperature-controlled logistics company is the latest in a string of California companies to move their headquarters to Music City.
Jerrell Shelton has been the CEO of Cryoport, Inc. (NASDAQ:CYRX) since 2012. This analysis aims first to contrast CEO...
We are still in the earliest days of the new decade, one sure to bring with it a plethora of changes. Some we can already foresee happening, while others remain unknowable to us.One certainty which will forever remain, though, involves investors’ hard-earned cash. Namely, everybody will always want to know where the best opportunities for ample returns lay.So, how to find out, then? As is de rigueur in the investment fraternity, the new year comes along with recommendation lists. Joining the fray is California based investment firm, Roth Capital. The company is adept at unearthing untapped potential with its primary focus on small-caps.We decided to get the scoop on 5 companies the investment firm thinks stand to make headway in 2020. All choices, according to the analysts, have room for solid upside, and, additionally, all currently hold a Strong Buy consensus rating from the Street. Here’s the lowdown.PowerFleet Inc (PWFL)Let’s start with one of Roth’s choices in the technology sector. Formerly known as I.D. Systems, PowerFleet is a pioneer in the use of radio frequency identification (RFID) technology for industrial asset tracking and management. With its patented systems for managing high value assets, the company serves big industry names such as Ford and Avis, as well as the U.S. Postal Service.The company’s latest earnings report achieved record quarterly revenue of $16.9 million, representing a year-over-year increase of 26%. The quarter also saw the company sign a number of deals with major players such as Knight-Swift, The Scotts Miracle-Gro Company, B.A.H. Express and Jungheinrich.In October PowerFleet completed the acquisition of Israeli based Pointer Telocation, a leading provider of telematics and mobile IoT solutions, for approximately $140 million. Roth’s William Gibson views “the combination as transformational, positioning the company for additional and larger orders.”“Our 2020 estimate is in line with guidance, earnings of $7.6 million or $0.26 per share on revenue of $153 million. Cross-selling opportunities are well underway and should result in meaningful upside to guidance,” the analyst said.Gibson, therefore, reiterated a Buy rating on PWFL, and kept his price target of $10.30 intact. Should the objective play out, gains of 46% could be heading investors’ way over the next 12 months. (To watch Gibson’s track record, click here)2 other analysts are currently tracking the asset tracker, with both recommending the stock a Buy. PowerFleet’s Strong Buy consensus rating is accompanied by an average price target of $10.83 and represents possible upside of 54%. (See PowerFleet stock analysis on TipRanks)Forty Seven Inc (FTSV)Moving on to the healthcare sector, we encounter Forty Seven Inc. The biotech is engaged in finding novel and more compassionate ways to fight cancer. FTSV has been turning heads on the Street recently, as December saw a tripling of its share price.The reason? Last month, Forty Seven announced promising updated clinical data from its ongoing phase Ib trial evaluating Magrolimab in combination with Azacitidine for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).The combination of Magrolimab and Azacitidine proved to be highly active and well-tolerated in patients with MDS and AML. Magrolimab is a humanized monoclonal antibody targeting CD47, which is a “don’t eat me” signal to macrophages and is expressed on all cells.After such a mercurial run up, what might move the stock even further?Roth’s Anthony Butler thinks It could be “inferences of magrolimab’s utility in solid tumors.” The 4-star analyst further expounded, “While we do not know the data, an early Phase Ib trial of magrolimab plus cetuximab in colorectal cancer will be presented at the Gastrointestinal Cancers Symposium (ASCO-GI) January 23-25 in San Francisco and as well as magrolimab plus avelumab in ovarian cancer at ASCO-SITC Clinical Immuno-Oncology Symposium February 6-8 in Orlando. The trials could possibly provide an early read on the utility of magrolimab in solid tumors. Any positive data most likely will increase the value of the stock.”Butler confirmed his bullish take on Forty Seven by reiterating a Buy rating on the cancer fighter. The analyst’s price target is $55 and implies upside potential of 56%. (To watch Butler’s track record, click here)It looks like the rest of the Street unanimously agrees with the Roth analyst. A Strong Buy consensus rating is formed of solely Buy ratings – 9, in fact. 13% upside could be in the cards should the average price target of $41.75 be achieved over the coming 12 months. (See Forty Seven stock analysis on TipRanks)NV5 Holdings (NVEE)NV5 Holdings suffered badly in the bull market of 2019, losing almost 17% of its value over the year. A series of disappointing earnings reports hampered the stock’s growth potential. The infrastructure-focused engineering and consulting company has started the new decade well, though, and is so far up by over 10% year-to-date.NV5 have been busy on the acquisition front; In December, the company completed the purchase of Geospatial Holdings (QSI), the US's largest independent geospatial analytics firm for approximately $318 million. The acquisition was the company’s 7th in 2019 alone.Roth’s Jeff Martin thinks a turnaround is due and foresees the trend extending further into 2020. The 5-star analyst said, “We chose NVEE as the top pick for Business Services in anticipation of the improved margin profile of the business in 2020. We model a 420bp improvement in adjusted EBITDA margin (on net revenue) to 21.2%, aided by the 24% margin from the QSI acquisition. QSI also brings organic growth potential and continued strength in NVEE’s Energy group aid in the return to organic growth in 2020.”Martin, accordingly, reiterated a Buy rating on NV5, along with a price target of $91. This implies upside potential of a not inconsiderable 63.5%. (To watch Martin’s track record, click here)Overall, those keeping an eye on NVEE stock remain with the bulls. NV5’s 3 Buy ratings coalesce into a Strong Buy consensus rating and come accompanied with an average price target of $87.33. The figure indicates upside potential of over 60% upside. (See NV5 stock analysis on TipRanks)Aspen Group Inc (ASPU)Combining tech with education, Aspen group has two for-profit universities under its holdings umbrella, Aspen University and United States University. The company provides online degrees along with on-campus studies.ASPU’s innovative monthly payment plan allows students to pursue degrees without the burden of student loans, while the university’s option to pay in monthly increments provides the ability to pay for education in significantly lower amounts. Aspen has been posting impressive growth figures in its latest earnings report, exhibiting 49% year-over-year growth, while also reporting record revenue of $12.1 million.Roth’s Darren Aftahi anticipates “continued topline growth (~36% y/y NTM) to be driven by further expansion of ASPU’s two higher growth and profit segments, USU and Pre-Licensure (PL).” The 5-star analyst further added, “We expect variable enrollment costs to be kept stable as ASPU should continue to benefit from its industry differentiating EdTech enrollment CRM (and with it double-digit conversion rates), suggesting continued leverage in marketing costs y/y, while maintaining double-digit enrollment growth (with upside in 2H20 from the launch of 2 additional PL campuses). Shares remain attractive trading at <2.5x FY21 revenue on ~30% y/y growth and runway for incremental profitability in the NTM.”Unsurprisingly, then, Aftahi kept his Buy rating on ASPU, along with his price target of $11. The figure indicates potential upside of 40%. (To watch Aftahi’s track record, click here)When put together, Aspen’s 4 Buy recommendations from the Street add up to a Strong Buy consensus rating. An average price target of $10.75 indicates possible gains of 36%. (See Aspen stock analysis on TipRanks)CryoPort Inc (CYRX)With Roth’s final pick we head back to the tech sector. Cryoport provide logistic solutions for the life sciences industry. Specifically, the company deals in the global transportation of temperature-sensitive materials and serves biopharmaceutical, IVF and surrogacy and animal health organizations around the world.The company is growing rapidly and making its way towards profitability. In 3Q19 revenues were up by 81% year-over-year with reported record revenue of $9.6 million. The company is expected to start turning a profit in 2021.After CYRX’s share price rose by over 150% in 2019’s first eight months, the final months of the year saw it experience a pullback. Roth’s Richard Baldry, though, sees the retracement as an opportunity. The 5-star analyst picks Cryoport’s as his “top Software sector pick for 2020.” Baldry said, “As CYRX’s clinical trial customer base increases and commercial therapies supported expand, we expect rapid growth and record revenue and earnings results in 2020, at odds with the roughly 40% pullback in its shares from recent highs.”To this end, Baldry reiterated a Buy on Cryoport, alongside a price target of $30. Should the target be met, investors stand to take home an increase in the shape of 75%. (To watch Baldry’s track record, click here)CYRX’s fans on the Street are few, yet vocal. Of the remaining 2 analysts chiming in with an opinion on the logistics company, both consider Cryoport a Buy. Therefore, Cryoport receives Strong Buy status. With an average price target of $23.67, the upside potential comes in at 38%. (See Cryoport price targets and analyst ratings on TipRanks)
Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced preliminary revenue for the twelve and three-month periods ended December 31, 2019, based upon preliminary unaudited financial information.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
10 is a majestic number. Used to bestow a quality of unmatched excellence, be it as a score in a gymnastics routine, or as a number on the back of a sportsman/woman’s shirt, indicating leadership and guru-like status.TipRanks makes good use of the aspirational number too. The Smart Score tool combines 8 key metrics that can indicate a stock’s long-term growth potential. The data is analyzed, and the stock is given a score accordingly. The highest score, naturally, is a “Perfect 10”.Setting out on our quest for perfection, with the Smart Score’s assistance, we homed in on 3 Perfect 10 Stocks with plenty of room for growth ahead. Let’s take a look.Yeti Holdings (YETI)Unicorn brands are a rare sight; hence they’re called - you guessed it - unicorn brands. The title refers to a privately held company that reaches a value of $1 billion. One such brand making quite a splash since going public is Yeti Holdings.The outdoor product manufacturer held its IPO in October 2018 and has mostly been on a cool upward trend ever since. It has made excellent progress in building its brand identity, seducing lovers of the outdoor lifestyle with its varied line of products. As a result, it now boasts 1.3 million followers on Instagram. Following previous strong quarters, 3Q continued the trend. Sales came in at $229M beating the $222M estimate, alongside increasing sales growth. Yeti delivered on EPS too - at $0.30 it beat the Street’s estimate of $0.26.Looking ahead, Jefferies’ 4-star analyst Randal Konik thinks the growth is set to continue, noting, “YETI is a brand that consumers (Pros/ Joes) love & also see as a gifting destination.” He adds, “We see significant opportunity for YETI to expand its TAM as it broadens its exposure to non-heritage markets in the US and international over the long-term. With continuous innovation in new and existing product categories, and a quickly growing margin-enhancing DTC channel, we believe top-line and margin opportunities are significant.” On the back of his analysis, Konik reiterated a Buy rating on Yeti, with a price target of $47.00, providing potential upside of almost 60%. (To watch Konik’s track record, click here)Another analyst singing YETI’s praises is Piper Jaffrey’s Peter Keith, who said, “Business momentum remains strong and we see upside to implied Q4 guidance. Importantly, we believe YETI is demonstrating longer-term growth potential, considering success with new product launches, steady/consistent gross margin expansion, intriguing store expansion opportunity both w/ Wholesale and DTC, and engaging marketing.” Like Konik, Keith reiterated a Buy on the stock, with a price target of $39.00. (To watch Keith’s track record, click here)The analysts’ positive sentiment is shared by the Street, as Yeti currently ranks as a Strong Buy. The cooler manufacturer has a consensus of 7 Buys and 1 Hold with an average price target of $40.50. This implies handsome potential upside of over 37% from its current price of $29.41. (See Yeti stock analysis on TipRanks)CryoPort (CYRX)With a motto of “Science. Logistics. Certainty.” CryoPort, which provides cold chain logistics solutions to the life sciences industry, presents itself boldly.In layman’s terms, it is a frozen shipping container company moving biological specimens around the world in sub-zero temperatures. Its clients include biopharmaceutical, IVF and surrogacy as well as animal health organizations across the globe.The company recently posted strong 3Q19 results, with revenue up 81% year-over-year, and positive adj. EBITDA for the second consecutive quarter. Among the highlights in the report were increased market share in the regenerative medicine clinical trial sector and a strategic partnership with Lonza. Lonza provides product development services to the pharmaceutical and biologic industries and is considered one of the largest players in the field. Needham’s 4-star analyst Stephen Unger thinks the partnership is good news for CryoPort, noting, “The goal of the partnership is to provide customers developing cell and gene therapies with a fully integrated solution for outsourced manufacturing and cold-chain logistics, which we see increasing customer visibility of CYRX's best-in-class logistics solutions earlier in the therapy development process.” Following the quarterly report and positive developments, Unger maintained his Buy rating on CYRX. His price target is $24.00. (To watch Unger’s track record, click here)B.Riley FBR’s Andrew D'Silva is also impressed with the partnership. The analyst said, “We believe Lonza has positioned itself as one of the cell and gene therapy industry's leading contract development and manufacturing organizations (CDMOs). As a result, we believe CYRX being selected as Lonza's preferred partner is another substantial validation for the company and should help further increase CYRX's logistics volumes.”To this end, D’Silva reiterated his Buy rating on CYRX stock, along with a price target of $26.00, providing potential upside of 70%. (To watch D’Silva’s track record, click here) Not many analysts have presently weighed in on the small cap’s potential for the year ahead. With a consensus of 2 Buys, CYRX currently ranks as a Moderate Buy. That being said, the average price target is $25.00, implying nice upside of almost 64% from its current price of $15.56. (See Cryoport stock analysis on TipRanks)Sonos (SONO)Speakers act louder than words, so the phrase goes. Well, not quite, but it does lead us nicely to our final choice.Consumer electronics company Sonos is mostly known for its smart speakers. Apart from the excellent sound quality, Sonos’ Sonoset system creates a custom Wi-Fi network, eliminating the need for old fashioned wires and allowing for music to be played simultaneously in different rooms. This is great for household systems, and earlier this year Sonos partnered with furniture giant Ikea on a new line of products, an alliance RBC Capital’s Robert Muller thinks has the potential to drive new customer adoption. The analyst said, “We believe the true value of Sonos lies in the family ecosystem whereby additional speakers complement one another. Once exposed to Sonos, we expect new customers to quickly envision the benefits of additional speakers throughout their homes. If SONO is able to expand the number of homes it's in (currently in ~8MM worldwide with nearly 4MM in the US), we should see a wave of secondary purchases.”Emphasizing this thesis, Muller says almost 4 out of 10 new purchases are from existing Sonos customers. Furthermore, the analyst also views SONO as a potential acquisition target for one of the tech giants, adding, “We do not believe current valuation adequately captures acquisition potential, expansion opportunities, or current baseline growth”. Following his analysis, Muller initiated coverage, along with a price target of $18.00. (To watch Muller’s track record, click here). A consensus rating of 3 Buys and 1 Hold means the Street is ready to turn the volume up on Sonos, rating the speaker manufacturer as a Strong Buy. The average price target is $18.25, providing upside of 24% from its current price of $14.70. (See Sonos stock analysis on TipRanks)
Cryoport now supports 425 clinical trials in Regenerative Medicine market Revenue from commercial therapies increased 368% over same quarter last year and 39% sequentially IRVINE, Calif. , Nov. 7, 2019 ...
- Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis - Partnership incorporates Cryoport's Cryoportal® Logistics Management Platform, SmartPak ...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
IRVINE, Calif., Oct. 31, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport" or the "Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2019 on Thursday, November 7, 2019 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Third Quarter 2019 in Review", which will provide a review of Cryoport's recent financial and operational performance and a general business update, will be issued by management at 4:05 pm ET on Thursday, November 7, 2019. Cryoport management will host a conference call at 5:00 pm ET on November 7, 2019.
While Cryoport, Inc. (NASDAQ:CYRX) shareholders are probably generally happy, the stock hasn't had particularly good...
IRVINE, Calif. , Oct. 9, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life sciences industry, announce a 3-year agreement to ensure safe and fully monitored transport of Adaptimmune’s cell therapies. This agreement with Cryoport will contribute to this, alongside other solutions including investment in the latest systems and technology, digitization of the supply chain information, and improved communications with patients and healthcare professionals. “Control and monitoring are critical because a simple temperature variation can jeopardize these cells and, ultimately, the product we supply to patients.
IRVINE, Calif., Sept. 18, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life sciences industry, today announced the launch of its Advanced Therapy Shipper™ product line for the regenerative medicine market. The Advanced Therapy Shipper™ guarantees each shipper has been used only for human use and provide complete traceability of all equipment, components and commodities. The result is unmatched verification information and unmatched supply chain support for biopharma companies researching and commercializing cell and gene therapies.
Collaboration between industry-leading supply chain orchestration (SCO) platform and the life sciences industry's most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities will bring the capabilities to support hundreds of advanced therapy clinical centers, clinical trials and commercially approved products worldwide. SAN FRANCISCO and IRVINE, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Vineti, Inc., and Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) announced a commercial partnership designed to extend end-to-end delivery of cell therapies and gene therapies to a growing number of patients as the industry continues to scale. Pairing Vineti’s supply chain orchestration (SCO) platform with Cryoport’s integrated temperature-controlled capabilities and near real-time monitoring will provide an end-to-end solution for advanced therapies, supporting the assurance of improved drug product quality and patient safety. Vineti and Cryoport together seek to leverage both of their commercial and clinical phase experiences and insights from serving biopharma customers.
BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.
Cryoport now supports 413 clinical trials in regenerative medicine Cryoport supports the commercial launch of bluebird bio's Zynteglo™ in Europe IRVINE, Calif. , Aug. 8, 2019 /PRNewswire/ -- Cryoport, ...
Every investor in Cryoport, Inc. (NASDAQ:CYRX) should be aware of the most powerful shareholder groups. Generally...
In addition to the earnings release, a document titled "Cryoport Second Quarter 2019 in Review", which will provide a review of Cryoport's recent financial and operational performance and a general business update, will be issued by management at 4:05 pm ET on Thursday, August 8. Cryoport management will host a conference call at 5:00 pm ET on August 8, 2019.
IRVINE, Calif., July 11, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) and EVERSANA™ have announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution.